The U.S. Food and Drug Administration (FDA) has accepted for review ChemoCentryx‘s application requesting the approval of avacopan to treat ANCA-associated vasculitis (AAV), the company announced in a press release. The agency expects to announce its decision regarding approval on or before July 7, 2021.
The 20S-proteasome — the core of an enzyme complex responsible for eliminating unnecessary or damaged proteins in cells — may be a useful biomarker of disease activity in people with ANCA-associated vasculitis (AAV), a study shows. The study, “Serum 20S proteasome levels are associated with…
Plasma exchange does not prolong the survival of patients with severe ANCA-associated vasculitis connected with diffuse alveolar hemorrhage, a potentially life-threatening condition in which blood starts to build up in the lungs, a study has found. The results challenge the notion that plasma exchange therapy might improve…
A combination of rituximab, plus glucocorticoids, is highly effective at re-inducing remission in patients with relapsed ANCA-associated vasculitis (AAV), according to a Phase 3 clinical trial. Trial findings were described in the study, “Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis,”…
ChemoCentryx is asking the U.S. Food and Drug Administration (FDA) to approve avacopan, a potential oral treatment for people with ANCA-associated vasculitis (AAV). The request, in the form of a new drug application (NDA), is based on data from the ADVOCATE Phase 3 trial (NCT02994927) in adult patients.
The Vasculitis Foundation awarded its “Dr. Chris Cox-Marinelli Young Investigator Award” — a one-year research grant totaling $49,822 — to Dragana Odobasic, PhD, a research fellow at Monash University in Melbourne, Australia. The award is for Odobasic”s research on a subset of specialized immune cells, called…
InflaRx announced it has fully enrolled the first part of its Phase 2 trial assessing the safety and efficacy of IFX-1 in people with ANCA-associated vasculitis (AAV) in Europe. The company also completed a blinded interim analysis into the potential impact of COVID-19 on this…
An instrument that assesses the nutritional status of individuals can be used to predict the prognosis of patients with ANCA-associated vasculitis, a study suggests. The study, “Controlling Nutritional Status Score is Associated with All-Cause Mortality in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis,” was published in the…
Work productivity of people with ANCA-associated vasculitis is influenced by their disease activity, the extent of organ damage, and their health-related quality of life, a study reports. The findings were presented in a poster, titled “Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage…
High levels of a small RNA molecule called miR-142-3p may impair the function of immune regulatory T-cells in people with granulomatosis with polyangiitis (GPA), a study has found. The study, “Increased miR-142-3p Expression Might Explain Reduced Regulatory T Cell Function in Granulomatosis With Polyangiitis,” was published…
Get regular updates to your inbox.